The Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair pricing and supply chain stability. India supplies nearly fifty percent of generic medicines to the United States. Tariffs alone will not produce sustainable generic medicine onshoring. Reforms should address upstream buying groups and delayed generic competition.

In 2025, India exported USD 9.7 billion worth of pharmaceuticals to the US, accounting for 38 per cent of its total global pharma exports of USD 25.8 billion. | India News

Trump announces a tariff timeline for generic drugs, starting with zero tariffs for a year, then escalating to 200%.

President Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028, rising to 200% a year later. The move…

US President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical exporters, but the country's cost advantage…

Donald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say the long-term impact may be limited.…

100% levy from 2028 could accelerate push into higher value medicines

The Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair pricing and supply chain stability.…

NEW DELHI: India's $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face…